Christian Lattermann has recently been appointed to the Brigham and Women’s Hospital at Harvard Medical School as Chief of Sports Medicine and Director of the Cartilage Repair Center. Until 2018 he was Professor and Vice Chair for Orthopaedic Surgery and Research at the University of Kentucky (UK), where he is the founder and Director of the Center for Cartilage Repair and Restoration. He is an expert in cartilage repair, outcomes research and clinical trials.Henning Madry is a clinician-scientist, a tenured Professor and Chair of Orthopedic Research and Director of the Center of Experimental Orthopedics at Saarland University in Germany. He is the founding Editor-in-Chief of the Journal of Experimental Orthopaedics, the basic science journal of the European Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA). As a clinically active orthopedic surgeon, he has special expertise in regenerative treatments for cartilage defects and osteoarthritis. His research translates novel molecular, cell biology and tissue engineering approaches into clinical applications in orthopedic surgery with a focus on translational aspects of osteochondral regeneration. Norimasa Nakamura is Professor at the Institute for Medical Science in Sports at Osaka Health Science University and the Global Center for Medical Engineering and Informatics at Osaka University. He is an orthopedic surgeon at the Osaka University Hospital, specializing in arthroscopic surgery and sports medicine. His current main interest is the development of three-dimensional tissue engineered constructs derived from various stem cells in joint tissue repair and regeneration. Norimasa Nakamura has been involved in the ICRS (serving as the President from 2015 to 2016) and ISAKOS (member of the board of directors from 2009 to 2013, the Chair of the scientific committee from 2013 to 2015, the Chair of the publication committee since 2019). Elizaveta Kon is an Associated Professor at Humanitas University, Milan, an orthopedic surgeon at the Center of Functional and Biological Reconstruction of the knee, Humanitas Research Hospital, Milan, and 2nd Vice President of the International Cartilage Regeneration & Joint Preservation Society (ICRS).Until 2017 she was Director of the Nano-Biotecnology Laboratory and an orthopedic surgeon at Rizzoli Orthopedic Institute, and Assistant Professor at University of Bologna. She has coordinated numerous research projects and clinical trials regarding biotechnology applications in orthopedics in the framework of Italian and European research.

• I Definition and Epidemiology.- 1 Definition of  “early Osteoarthritis” .- 2 Early signs of OA in x-rays.- 3 MRI measures of early OA – the ACL-OA score.- 4 Relaxometrie as early measure of OA.- 5 Epidemiology of Osteoarthritis and the importance of early onset-Katz (or delegate).- 6 Economic aspects of early OA.- 7 Frequency, Epidemiology and Cost of ACL injuries.- 8 The human ACL injury model of early OA.- 9 The risk of early OA after joint fracture.- 10 The clinical manifestation of early OA.- II Basic science aspects of the disease process.- 11 Biomechanics of instability and its relationship to OA.- 12 Fluid dynamics and rheology in the arthritic joint.- 13 How does articular cartilage actually break down?.- 14 Early OA after tibial plateau fracture in the rat.- 15 Matrix degradation after injury.- 16 Collagen breakdown in hip and knee joint over time.- 17 Inflammation after ACL injury.- 18 The role of the “Inflammatype”.- 19 Immune response and early OA.- 20Macrophages in early OA.- 21 Vesicles and MSC’s.- III Clinical Treatment of early OA (non-op).- 22 Early clinical manifestations of early OA.- 23 When is a chondral defect relevant?.- 24 Role of cortisone in the treatment of early OA.- 25 Viscosupplementation in early OA.- 26 The role of PRP in early OA.- 27 What is the current role and promise of stem cell therapy in early OA.- 28 Role of iPS cells for OA?.- 29 Fat derived stem cells.- 30 BMAC.- IV Clinical Treatment of early OA (operative).- 30 The role of alignment in the treatment of early OA.- 31 Meniscus injury and early OA, when to operate, when to repair, when to resect?.- 32 Role of arthroscopic debridement, microfracture or washouts.- 33 Osteochondral allograft for early OA.- 34 Cell based procedures for early OA.- 35 Chondral defect repair using a coral based implant.- 36 Options for Early Osteoarthritis treatment in the Shoulder.

Christian Lattermann has recently been appointed to the Brigham and Women’s Hospital at Harvard Medical School as Chief of Sports Medicine and Director of the Cartilage Repair Center. Until 2018 he was Professor and Vice Chair for Orthopaedic Surgery and Research at the University of Kentucky (UK), where he is the founder and Director of the Center for Cartilage Repair and Restoration. He is an expert in cartilage repair, outcomes research and clinical trials.Henning Madry is a clinician-scientist, a tenured Professor and Chair of Orthopedic Research and Director of the Center of Experimental Orthopedics at Saarland University in Germany. He is the founding Editor-in-Chief of the Journal of Experimental Orthopaedics, the basic science journal of the European Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA). As a clinically active orthopedic surgeon, he has special expertise in regenerative treatments for cartilage defects and osteoarthritis. His research translates novel molecular, cell biology and tissue engineering approaches into clinical applications in orthopedic surgery with a focus on translational aspects of osteochondral regeneration. Norimasa Nakamura is Professor at the Institute for Medical Science in Sports at Osaka Health Science University and the Global Center for Medical Engineering and Informatics at Osaka University. He is an orthopedic surgeon at the Osaka University Hospital, specializing in arthroscopic surgery and sports medicine. His current main interest is the development of three-dimensional tissue engineered constructs derived from various stem cells in joint tissue repair and regeneration. Norimasa Nakamura has been involved in the ICRS (serving as the President from 2015 to 2016) and ISAKOS (member of the board of directors from 2009 to 2013, the Chair of the scientific committee from 2013 to 2015, the Chair of the publication committee since 2019). Elizaveta Kon is an Associated Professor at Humanitas University, Milan, an orthopedic surgeon at the Center of Functional and Biological Reconstruction of the knee, Humanitas Research Hospital, Milan, and 2nd Vice President of the International Cartilage Regeneration & Joint Preservation Society (ICRS).Until 2017 she was Director of the Nano-Biotecnology Laboratory and an orthopedic surgeon at Rizzoli Orthopedic Institute, and Assistant Professor at University of Bologna. She has coordinated numerous research projects and clinical trials regarding biotechnology applications in orthopedics in the framework of Italian and European research.

• I Definition and Epidemiology.- 1 Definition of  “early Osteoarthritis” .- 2 Early signs of OA in x-rays.- 3 MRI measures of early OA – the ACL-OA score.- 4 Relaxometrie as early measure of OA.- 5 Epidemiology of Osteoarthritis and the importance of early onset-Katz (or delegate).- 6 Economic aspects of early OA.- 7 Frequency, Epidemiology and Cost of ACL injuries.- 8 The human ACL injury model of early OA.- 9 The risk of early OA after joint fracture.- 10 The clinical manifestation of early OA.- II Basic science aspects of the disease process.- 11 Biomechanics of instability and its relationship to OA.- 12 Fluid dynamics and rheology in the arthritic joint.- 13 How does articular cartilage actually break down?.- 14 Early OA after tibial plateau fracture in the rat.- 15 Matrix degradation after injury.- 16 Collagen breakdown in hip and knee joint over time.- 17 Inflammation after ACL injury.- 18 The role of the “Inflammatype”.- 19 Immune response and early OA.- 20Macrophages in early OA.- 21 Vesicles and MSC’s.- III Clinical Treatment of early OA (non-op).- 22 Early clinical manifestations of early OA.- 23 When is a chondral defect relevant?.- 24 Role of cortisone in the treatment of early OA.- 25 Viscosupplementation in early OA.- 26 The role of PRP in early OA.- 27 What is the current role and promise of stem cell therapy in early OA.- 28 Role of iPS cells for OA?.- 29 Fat derived stem cells.- 30 BMAC.- IV Clinical Treatment of early OA (operative).- 30 The role of alignment in the treatment of early OA.- 31 Meniscus injury and early OA, when to operate, when to repair, when to resect?.- 32 Role of arthroscopic debridement, microfracture or washouts.- 33 Osteochondral allograft for early OA.- 34 Cell based procedures for early OA.- 35 Chondral defect repair using a coral based implant.- 36 Options for Early Osteoarthritis treatment in the Shoulder.